HyperkalemiaTreatment Market, by Drug Type (IV Calcium, Insulin, Sodium Bicarbonate,Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others), by Route ofAdministration (Oral and Intravenous, Inhalation, Rectal), by DistributionChannel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Geography(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Hyperkalemia is a diseases in which levels of potassium are higherthan normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsiblefor managing potassium balance in the body by regulating its excretion as wellas its intake. A person is prone to develop hyperkalemia when the consumptionof potassium exceeds that of kidneys’ potential to excrete it. The right amountof potassium and sodium in the body play a vital role in normal functioning ofthe myocardium.
Hyperkalemia can occur due to congestive heart failure,chronic kidney disease, or diabetic kidney disease. The condition can alsooccur when a patient receives renin-angiotensin-aldosterone system inhibitors(RAAS) in kidney disease. Abnormal levels of potassium can lead to irregularheartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioningtest, creatinine blood test, blood tests, and glucose monitoring.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2406
Hyperkalemia Treatment Market– Dynamics
Increase in prevalence of cardiac arrhythmias and chronickidney disease are major factors driving growth of hyperkalemia treatmentmarket during the forecast period. According to Centers for Disease Control andPrevention (CDC) report, in 2017 around 30 million or 15% people suffer fromchronic kidney diseases in the U.S. Increasing number of people suffering fromlifestyle-associated diseases also leads to high prevalence of hyperkalemia,which in turn boost growth of the market.
Hyperkalemia Treatment Market – Regional Insights
On the basis of geography, the global hyperkalemia treatmentmarket is segmented into North America, Latin America, Europe, Asia Pacific,Middle East, and Africa. North America is expected to hold dominant position inthe global hyperkalemia treatment market followed by Europe during the forecastperiod.
The U.S. holds a dominant position in North America marketdue to development in healthcare infrastructure, and Unhealthy lifestyle of U.Sof citizen. As incidence of hyperkalemia has been reported anywhere from 2.6%to 3.2% which is highest among others region.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/hyperkalemia-treatment-market-2406
Furthermore, Asia Pacific hyperkalemia treatment market isexpected to witness significant growth due increasing launches of drugs for thetreatment of hyperkalemia. For instance, In May 2018, The U.S. Food and DrugAdministration (U.S FDA) approved AstraZeneca’s, Lokelma a drug that isinsoluble, non-absorbed sodium zirconium silicate, oral suspension and acts asa highly-selective potassium-removing agent for the treatment of hyperkalemiain adults.
Similarly, in October 2015, the U.S FDA approved Relypsa,Inc.’s., Veltassa a drug to treat hyperkalemia.
Hyperkalemia Treatment Market - Competitive Landscape
Major players operating in the hyperkalemia treatment marketinclude, AstraZeneca, Klarvoyant Biogenics Pvt. Ltd, Concordia PharmaceuticalsInc, Steadfast MediShield Pvt. Ltd, Perrigo Company plc, AdvaCare Pharma, EliLilly and Company, Carolina Medical Products, Relypsa, Inc., RSM Kilitch PharmaPvt. Ltd, Novel Laboratories, and others.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2406
About CoherentMarket Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
